FDA_Warning_Letters, Import_Alerts_&_EU_Non-Compliances_in_2019
X

Find FDA Investigational New Drug (IND) Submissions for Oncology

A collaboration with SCORR Marketing

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
Country filter
    News Type filter
      Company filter
        Product Type filter
          Deal Size filter
            refresh

            Product Type

            Companies

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): ND021

            Therapeutic Area: Oncology

            Highest Development Status: IND Enabling Product Type: Large molecule

            Partner/Sponsor/Collaborator: 3SBio

            Deal Size: $23.8 million Upfront Cash: Undisclosed

            Deal Type: Series B Financing March 09, 2020

            Details:

            With the financing secured, Numab plans to further broaden its proprietary pipeline and accelerate the development for a number of programs towards the clinic.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): PCLX-001

            Therapeutic Area: Oncology

            Highest Development Status: IND Enabling Product Type: Small molecule

            Partner/Sponsor/Collaborator: Canadian angel investors

            Deal Size: $3.9 million Upfront Cash: Undisclosed

            Deal Type: Financing March 04, 2020

            Details:

            These funds will support advancing the Company’s first product, PCLX-001, to clinical trials anticipated to start later this year.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): AMX-818

            Therapeutic Area: Oncology

            Highest Development Status: IND Enabling Product Type: Large molecule

            Partner/Sponsor/Collaborator: Omega Funds

            Deal Size: $73.0 million Upfront Cash: Undisclosed

            Deal Type: Series A Financing March 04, 2020

            Details:

            Amunix plans to utilize the Series A proceeds to advance its lead development candidate, AMX-818, to progress earlier discovery stage XPAT programs and to initiate XPAC discovery work.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): ITI-1001

            Therapeutic Area: Oncology

            Highest Development Status: IND Enabling Product Type: Vaccine

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable March 03, 2020

            Details:

            In the planned First-In-Human (FIH) Phase I trial, Immunomic will evaluate the safety, tolerability, immunogenicity and preliminary efficacy of ITI-1001.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): DT2216

            Therapeutic Area: Oncology

            Highest Development Status: IND Enabling Product Type: Undisclosed

            Partner/Sponsor/Collaborator: Cancer Prevention & Research Institute of Texas

            Deal Size: $3.0 million Upfront Cash: Undisclosed

            Deal Type: Funding February 26, 2020

            Details:

            Dialectic will use the funding to further the development of its lead product candidate, DT2216.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): DSP107,Atezolizumab

            Therapeutic Area: Oncology

            Highest Development Status: IND Enabling Product Type: Large molecule

            Partner/Sponsor/Collaborator: Flerie Invest AB

            Deal Size: $18.0 million Upfront Cash: Undisclosed

            Deal Type: Funding February 25, 2020

            Details:

            Proceeds will be used for advancing the Company's next generation immuno-oncology drug candidates including the clinical development of the Company's lead product, DSP107, an anti-CD47 therapy.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): MGTA-117

            Therapeutic Area: Oncology

            Highest Development Status: IND Enabling Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable February 24, 2020

            Details:

            MGTA-117 demonstrated robust anti-tumor activity in xenograft models from patients with refractory leukemia

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): ELI-002

            Therapeutic Area: Oncology

            Highest Development Status: IND Enabling Product Type: Vaccine

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable February 19, 2020

            Details:

            ELI-002 has been shown in preclinical studies to enhance the magnitude and functional characteristics of KRAS-specific immunity important for a robust anti-tumor effect.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): ELI-002

            Therapeutic Area: Oncology

            Highest Development Status: IND Enabling Product Type: Vaccine

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable February 11, 2020

            Details:

            Collaboration will conduct a multicenter Phase 1/2 study of ELI-002, an Amphiphile immuno-oncology therapeutic targeting KRAS mutations in the adjuvant setting for patients with PDAC.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Cotsiranib

            Therapeutic Area: Oncology

            Highest Development Status: IND Enabling Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable February 10, 2020

            Details:

            Third such designation for this drug candidate, following the designation for Primary Sclerosing Cholangitis and Cholangiocarcinoma.

            PharmaCompass